for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Iovance Biotherapeutics Inc

IOVA.OQ

Latest Trade

20.94USD

Change

0.22(+1.06%)

Volume

2,136,448

Today's Range

20.66

 - 

21.63

52 Week Range

7.27

 - 

26.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
20.72
Open
20.90
Volume
2,136,448
3M AVG Volume
29.29
Today's High
21.63
Today's Low
20.66
52 Week High
26.55
52 Week Low
7.27
Shares Out (MIL)
123.83
Market Cap (MIL)
2,593.01
Forward P/E
-14.01
Dividend (Yield %)
--

Next Event

Iovance Biotherapeutics Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Iovance Biotherapeutics Files For Mixed Shelf Of Up To $400 Million

Iovance Biotherapeutics Reports Q2 Loss Per Share $0.38

Iovance Biotherapeutics Provides Cervical Cancer Program Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Industry

Biotechnology & Drugs

Contact Info

999 Skyway Rd Ste 150

+1.650.2607120

http://www.iovance.com/

Executive Leadership

Iain Dukes Dukes

Chairman of the Board

Maria Fardis

President, Chief Executive Officer and Director

Timothy E. Morris

Chief Financial Officer and Corporate Secretary

Frederick G. Vogt

General Counsel

Friedrich Graf Finckenstein

Chief Medical Officer

Key Stats

1.56 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.850

2017

-1.410

2018

-1.270

2019(E)

-1.494
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
6.52
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-44.87
Return on Equity (TTM)
-41.88

Latest News

BRIEF-Iovance Biotherapeutics Announces Pricing Of Its Public Offering Of $150 Million Of Common Stock

* IOVANCE BIOTHERAPEUTICS, INC. ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF $150 MILLION OF COMMON STOCK

BRIEF-Iovance Announces Preliminary Phase 2 Data For Til Treatment In Head And Neck And Cervical Cancers

* IOVANCE BIOTHERAPEUTICS ANNOUNCES PRELIMINARY PHASE 2 DATA FOR TIL TREATMENT IN HEAD AND NECK AND CERVICAL CANCERS

BRIEF-Iovance Biotherapeutics‍ Intends To Offer And Sell $125 Mln Of Its Common Stock

* IOVANCE BIOTHERAPEUTICS, INC. ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Iovance Biotherapeutics Files For Mixed Shelf Of Up To $250 Mln

* IOVANCE BIOTHERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING Source text: (http://bit.ly/2zKJhqw) Further company coverage:

BRIEF-Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates

* IOVANCE BIOTHERAPEUTICS ANNOUNCES MANUFACTURING DECISION, PROVIDES CLINICAL UPDATES AND HIGHLIGHTS PIPELINE EXPANSION AT ANALYST DAY 2017

BRIEF-Iovance Biotherapeutics reports Q3 GAAP loss per share $0.35

* Iovance Biotherapeutics Inc reports third quarter 2017 financial results

BRIEF-Iovance Biotherapeutics announces pricing of its public offering of $50 mln of common stock

* Iovance Biotherapeutics, Inc. announces pricing of its public offering of $50 million of common stock

BRIEF-Iovance BioTherapeutics plans to offer $50 mln of common stock​

* Intends to use proceeds from this offering to fund its ongoing clinical trials for its current candidates Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Iovance Biotherapeutics announces approval of 1st clinical trial of LN-145 for treating cervical cancer

* Iovance Biotherapeutics announces approval of first clinical trial application by competent authority in Netherlands for a phase 2 trial of LN-145 for the treatment of patients with cervical cancer Source text for Eikon: Further company coverage:

BRIEF-Iovance Biotherapeutics enters into a research collaboration with the Ohio State University Comprehensive Cancer Center

* Iovance Biotherapeutics enters into a research collaboration focused on hematologic malignancies with the Ohio State University Comprehensive Cancer Center

BRIEF-Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma

* Iovance Biotherapeutics announces FDA fast track designation for LN-144 for treatment of advanced melanoma Source text for Eikon: Further company coverage:

BRIEF-Iovance Biotherapeutics appoints Timothy Morris as chief financial officer

* Iovance Biotherapeutics appoints Timothy Morris as Chief Financial Officer

BRIEF-Iovance Biotherapeutics loss $0.32/shr

* Iovance Biotherapeutics reports second quarter 2017 financial results

BRIEF-Iovance Biotherapeutics Inc - appointed Franco Valle as interim principal financial officer of company

* Iovance Biotherapeutics Inc - on July 26 company appointed Franco Valle to serve as interim principal financial officer of company Source text: (http://bit.ly/2u3g3QI) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up